Welcome to our dedicated page for Ionis Pharmaceuticals SEC filings (Ticker: IONS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ionis Pharmaceuticals’ 10-K doesn’t just list numbers; it weaves together antisense pipeline updates, milestone revenues from Biogen and AstraZeneca, and detailed R&D spend that often tops hundreds of millions. Parsing how each clinical program moves from discovery to Phase 3—and how those decisions flow through revenue recognition rules—can be overwhelming.
Stock Titan’s AI lifts that burden. Our platform delivers Ionis Pharmaceuticals SEC filings explained simply, turning the dense language of a 300-page annual report into plain-English takeaways. Get real-time alerts whenever an Ionis Pharmaceuticals 8-K material events explained filing hits EDGAR, see Ionis Pharmaceuticals insider trading Form 4 transactions the moment executives trade shares, and drill into each Ionis Pharmaceuticals quarterly earnings report 10-Q filing with side-by-side historical comparisons. Need to monitor Ionis Pharmaceuticals executive stock transactions Form 4? Our AI tags every purchase, sale or option exercise and flags unusual patterns.
Whether you’re projecting future royalty streams, checking how Ionis accounts for partner reimbursements, or reviewing CEO pay in the Ionis Pharmaceuticals proxy statement executive compensation, you’ll find every document—10-K, 10-Q, 8-K, S-8 and more—indexed and searchable. Interactive summaries, key metric dashboards, and sentence-level citations let you understand Ionis Pharmaceuticals SEC documents with AI in minutes, not hours. Follow upcoming catalysts with Ionis Pharmaceuticals earnings report filing analysis or set custom alerts for Ionis Pharmaceuticals Form 4 insider transactions real-time; Stock Titan turns regulatory complexity into actionable clarity.
Brett Monia, who is listed as both a director and the Chief Executive Officer of Ionis Pharmaceuticals, purchased 189 shares of Ionis Pharmaceuticals, Inc. common stock on 08/29/2025 under the company’s Amended and Restated 2000 Employee Stock Purchase Plan at a per-share price of $27.71. Following the transaction the filing reports 180,009 shares beneficially owned. The purchased shares are subject to a sale restriction and may not be sold until 03/02/2026. The Form 4 was signed by an attorney-in-fact on behalf of Brett Monia on 09/03/2025.
Richard S. Geary, Executive Vice President and Chief Development Officer of Ionis Pharmaceuticals (IONS), reported a purchase of 165 shares of Ionis common stock on 08/29/2025 at a price of $27.71 per share under the company’s Amended and Restated 2000 Employee Stock Purchase Plan. After this transaction, he beneficially owns 89,657 shares directly. The reporting disclosure notes these purchased shares may not be sold until March 2, 2026, indicating a holding restriction tied to the plan.
C. Frank Bennett, EVP and Chief Scientific Officer of Ionis Pharmaceuticals (IONS), reported an employee stock purchase on 08/29/2025. The filing shows 213 shares of Ionis common stock were acquired at a price of $27.71 under the company’s Amended and Restated 2000 Employee Stock Purchase Plan. Following the transaction the filing lists 93,679 shares beneficially owned (direct). The purchased shares are subject to a sale restriction and may not be sold until March 2, 2026. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Bennett on 09/03/2025.
Brian Birchler, EVP of Corporate and Development Operations at Ionis Pharmaceuticals (IONS), reported an insider purchase of 56,826 shares of Ionis common stock on 08/29/2025 at a price of $27.71 per share. The filing indicates these shares were acquired under the company’s Amended and Restated 2000 Employee Stock Purchase Plan and may not be sold until March 2, 2026. The Form 4 was executed by an attorney-in-fact and reflects that the shares are directly beneficially owned following the transaction.
Form 144 filed for Ionis Pharmaceuticals (IONS) reports a proposed sale of 16,000 shares of common stock via Stifel Nicolaus with an aggregate market value of $962,371.00. The filing lists approximately 159,391,229 shares outstanding and an approximate sale date of 09/03/2025 on Nasdaq. The shares were acquired by option exercise on 07/01/2016 and the proposed payment method is cash. The filer reports no securities sold in the past three months.
Ionis Pharmaceuticals (IONS) reported a Form 144 notice for a proposed sale of 124,850 shares of common stock to be handled by Stifel Nicolaus & Company, Inc. on 09/03/2025 on Nasdaq with an aggregate market value of $7,634,553.00. The shares were acquired on 01/04/2021 through an option exercise from the issuer and the planned consideration is cash. The filing also discloses a recent sale by Patrick O'Neil of 13,050 shares on 09/02/2025 for gross proceeds of $711,418.00. The filing includes the statutorily required declaration that the seller is not aware of undisclosed material adverse information.
Ionis Pharmaceuticals Form 144 notice: A proposed sale of 51,800 shares of common stock is reported to be executed through Stifel Nicolaus & Company, Inc. on 09/03/2025 with an aggregate market value of $3,152,698.00. The filing lists total shares outstanding of 159,391,229. Acquisition details for the shares to be sold are disclosed: 46,800 were acquired by option exercise on 01/03/2022, 7,537 were restricted stock units dated 01/15/2017, and 6,373 were restricted stock units dated 01/15/2016. The filing also reports sales by Frank Bennett in the past three months: 10,000 shares on 08/18/2025 for $439,776.00, and two sales on 09/02/2025 of 2,374 (proceeds $116,658.00) and 2,626 (proceeds $129,042.00). The filer signs a standard representation that no material nonpublic information is known. Other issuer contact and relationship fields are not populated in the provided content.
Ionis Pharmaceuticals (IONS) submitted a Form 144 notifying the proposed sale of 45,000 shares of common stock through Stifel Nicolaus & Company, with an aggregate market value of $2,658,996.00. The filing lists 159,391,229 shares outstanding and names Nasdaq as the exchange with an approximate sale date of 09/03/2025.
The securities were acquired by the seller on 01/31/2022 via an option exercise for 60,000 shares. The planned method of payment on sale is cash. The filing reports no securities sold by the person in the past three months and contains the standard attestation about absence of undisclosed material adverse information.
Form 144 filed for Ionis Pharmaceuticals (IONS) reports a proposed sale of common stock. The broker listed is Stifel Nicolaus & Company. The notice covers 203,814 shares with an aggregate market value of $12,230,307, to be sold approximately on 09/03/2025 on Nasdaq. The filer shows prior option-exercise acquisitions: 101,489 shares on 01/03/2022, 42,030 shares on 01/03/2023 and 102,900 shares on 01/01/2019, with payment in cash. Two small open-market sales by Brett Monia in July 2025 are also disclosed.
Ionis Pharmaceuticals (IONS) filed a Form 144 notifying a proposed sale of 3,162 shares of common stock to be executed through Stifel Nicolaus & Company on 09/03/2025. The filing reports an aggregate market value of $192,958.00 based on total shares outstanding of 159,391,229. The shares were acquired by option exercise: 928 shares on 01/03/2022 and 2,234 shares on 01/03/2023, with cash payment noted on the planned sale date. The filing includes the standard seller representation that no material nonpublic information is known to the selling person and indicates no securities sold in the past three months.
FAQ
What is the current stock price of Ionis Pharmaceuticals (IONS)?
What is the market cap of Ionis Pharmaceuticals (IONS)?
